In the next few days and weeks we’ll see the first wave of reactions from health plans – and unsubsidized Affordable Care Act exchange shoppers, because of premium increases – to President Trump’s decision to cut off immediately the cost-sharing subsidies to health plans participating in the exchanges.
All new members are welcome to stop by this post’s comment section to introduce themselves. Continue reading
The Trump administration dealt a one-two punch to the Affordable Care Act on Thursday. Trump’s executive order would give Americans the option of buying lower-cost health insurance, but also could usher back the bare-bones insurance options that the Affordable Care Act was designed to eliminate.
In addition, Trump directed the U.S. Department of Health and Human Services to end the cost-sharing reduction payments (CSRs) to health insurers required under the ACA effective immediately. The payments always have been controversial, and the Trump administration, in justifying its action, noted that House Republicans earlier successfully challenged them in court. Continue reading
The Association of Health Care Journalists has announced the selection of a new class of AHCJ-CDC Health Journalism Fellows. The 11 journalists – supported through a grant from the Leona M. and Harry B. Helmsley Charitable Trust – will spend a week studying a variety of public health issues at two Atlanta campuses of the Centers for Disease Control and Prevention.
The AHCJ-directed fellowship program will include presentations, roundtable discussions and lab tours on epidemiology, global disease prevention efforts, obesity and other chronic diseases, vaccine safety, foodborne disease, influenza, antibiotic resistance, climate change and other topics.
Proove Biosciences, a genetic testing company in Irvine, Calif., was placed into court-ordered receivership at the end of August for “restructuring and asset sale.” Proove’s founder and former CEO Brian Meshkin has blamed the company’s financial problems on investigative articles that Charles Piller, West Coast editor for Stat, wrote about the company’s lead product over the last several months, according to Pillar’s coverage of the receivership proceedings.
Meshkin, who called Piller’s reporting about Proove “erroneous and damaging.” He claimed that stories were based on false allegations from disgruntled employees, ignoring that Piller also had quoted genetic testing experts skeptical of the scientific claims behind the Proove Opioid Risk test. Proove has marketed the test as a way for doctors to predict a patient’s likelihood of becoming addicted to opioids. Continue reading